The role of the intestinal microbiota in host cardiometabolic health and disease has gained significant attention over recent decades. Previous studies have shown effects on metabolic health throug...
Expert groups argue to raise the recommended daily allowance for protein in older adults from 0.8 to 1.2 g/kg/day to prevent undernutrition. However, protein is thought to increase satiety, possibly through effects on gut microbiota and central appetite regulation. If true, raising daily protein intake may work counterproductively. In a randomized controlled trial, we evaluated the effects of dietary advice aimed at increasing protein intake to 1.2 g/kg adjusted body weight/day (g/kg aBW/day) on appetite and gut microbiota in 90 community-dwelling older adults with habitual protein intake <1.0 g/kg aBW/day (Nintervention = 47, Ncontrol = 43). Food intake was determined by 24-h dietary recalls and gut microbiota by 16S rRNA sequencing. Functional magnetic resonance imaging (fMRI) scans were performed in a subgroup of 48 participants to evaluate central nervous system responses to food-related stimuli. Both groups had mean baseline protein intake of 0.8 ± 0.2 g/kg aBW/day. At 6 months’ follow-up this increased to 1.2 ± 0.2 g/kg aBW/day for the intervention group and 0.9 ± 0.2 g/kg aBW/day for the control group. Microbiota composition was not affected, nor were appetite or brain activity in response to food-related stimuli. Increasing protein intake in older adults to 1.2 g/kg aBW/day does not negatively impact the gut microbiota or suppress appetite.
Animal studies suggest that short-chain fatty acids acetate and butyrate are key players in the gut-brain axis and may affect insulin sensitivity. We investigated the association of intestinal acetate and butyrate availability (measured by butyryl-coenzyme A transferase (ButCoA) gene amount) with insulin sensitivity and secretion in healthy subjects from the HELIUS cohort study from the highest 15% (N = 30) and the lowest 15% (N = 30) intestinal ButCoA gene amount. The groups did not differ in insulin sensitivity or secretion. However, the high ButCoA group showed lower glucose and insulin peaks during the first 60 min after a meal and a higher nadir during the second 60 min (p < 0.01), suggesting delayed glucose adsorption from the small intestine. Our data suggest that chronically increased acetate and butyrate availability may improve glucose metabolism by delaying gastric emptying and intestinal adsorption. Future studies should further investigate the effect of acetate and butyrate interventions.
Purpose: Roux-en-Y gastric bypasses (RYGB) are frequently accompanied by long-term gastrointestinal (GI) symptoms. Direct mechanistic insight into the causation of these symptoms is lacking, but changes in the intestinal microbiome have been proposed to play a role. With this study, we aimed to investigate whether a microbial predisposition exists before RYGB which is associated with GI symptoms during follow-up and to evaluate which microbial groups are involved. Materials and Methods: In total, 67 RYGB patients were included. Shotgun metagenomic sequencing was performed on fecal samples obtained just before and 1 year after surgery. To assess GI symptoms, patients filled out Gastrointestinal Quality of Life Index (GIQLI) questionnaires and were divided into groups based on their total GIQLI score and change in score (postsurgery versus baseline). Extremely randomized tree predictor models were used to identify the most distinctive microbial species associated with postoperative GI symptoms. Results: Beta diversity differed significantly between baseline and 1-year post-surgery samples, with the post-surgery microbiome resembling a more dysbiotic profile. The most predictive species regarding total GIQLI (AUC 0.77) or delta GIQLI score (AUC 0.83) were identified. Many of these species are known butyrate producers or species known to support them and/or species with anti-inflammatory properties, including Coprococcus eutactus, Faecalibacterium prausnitzii, and Ruminococcus callidus. Conclusion: Beneficial commensal gut microbiota related to a high GI score were associated to adequate intestinal fermentative capacity, suggesting these species might have protective properties against postoperative GI malfunctioning. Graphical
People with obesity tend to have altered functional connectivity of reward-related areas in the brain, contributing to overeating and weight gain. The gut-brain axis may function as a mediating factor, with gut-derived short-chain fatty acids (SCFAs) as possible intermediates in the relationship between microbiota and functional connectivity. We investigated the influence of SCFA turnover on resting state functional connectivity in healthy individuals with extremely high and extremely low levels of intestinal SCFA turnover. In this study, we included individuals with low or high intestinal SCFA turnover (estimated by fecal concentration of the butyryl-coenzyme A (CoA)-transferase (ButCoA) gene). Resting state functional magnetic resonance imaging (rs-fMRI) was used to assess functional connectivity of eight regions of interest (ROIs) either directly involved in the mesolimbic dopaminergic network (amygdala, hippocampus, caudate nucleus, putamen and nucleus accumbens) or primary projection regions of this network (middle frontal gyrus, superior frontal gyrus, insula). Functional connectivity was assessed using connectivity strength and eigenvector centrality. No differences in connectivity strength or eigenvector centrality were observed between the high and the low ButCoA group in any of our ROIs, suggesting SCFA turnover is not associated with resting state functional connectivity of central reward-related areas. Although previous studies provide evidence for an association between gut microbiota and resting state functional connectivity of reward-related areas, our findings do not support the hypothesis that this relationship is mediated by SCFAs. This suggests the existence of alternative mechanisms via which the intestinal microbiota may affect appetite, beyond local SCFA production.
Background: Microbiota-derived short-chain fatty acid acetate has improved glucose metabolism and reduced appetite in animal studies and some preliminary human trials. However, other experiments show contradicting results, with acetate inducing hyperphagia and insulin resistance. Objective: Study the effects of acute intravenous acetate infusion on postprandial insulin and glucose responses and on central responsivity in fasted state. Design: We performed a randomised placebo-controlled crossover trial, including 18 lean individuals and 19 individuals with metabolic syndrome. We administered sodium acetate intravenously for 3 hours. We performed a standardised mixed meal test and employed a functional MRI (fMRI) paradigm, including a food-cue task and a food-receipt task. Results: Acetate infusion did not significantly affect postprandial glucose or insulin levels or fasted fMRI results. Remarkably, plasma acetate levels decreased significantly after meal ingestion despite the constant acetate infusion rate. Fractional urinary acetate excretion significantly increased upon infusion but contained only 1–2% of the total amount of acetate infused. Conclusion: Our data do not support effects of increased plasma acetate levels on glucose metabolism or blood oxygen level-dependent signal response to food-related stimuli in humans. These findings suggest that previously established positive effects of acetate are not dependent on acute rises in plasma acetate and may be primarily mediated through intestinal hormone release and the gut–brain axis—a route of effect that is bypassed in this current study. Finally, the decreasing acetate concentrations upon meal ingestion raise the question what tissues absorb or metabolise acetate in the postprandial phase. Trial registration number: NL8381.